Results 51 to 60 of about 60,209 (283)
Saudi Journal of Kidney Diseases and Transplantation, 2019 Cytomegalovirus (CMV) is one of opportunistic infections post solid organ transplant and remains a cause of morbidity and mortality. Mammalian target of rapamycin inhibitors has a theoretical antiviral advantage compared to conventional immunosuppression.
Ali M Shendi +4 more
doaj +1 more source
Pneumopathie médicamenteuse sous sirolimus : interaction avec l’atorvastatine ? [PDF]
, 2012 Introduction Sirolimus is an immunosupressant used in renal transplantation because of its lack of nephrotoxicity. We report four cases of pneumonitis due to sirolimus, possibly revealing an interaction with atorvastatin.
A. Foulet-Rogé +6 more
core +3 more sources
South African Medical Journal, 2016 Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR), used as an immunosuppressant for solid-organ transplant recipients and patients with autoimmune disorders. We report a case of lymphoedema, a rare complication of sirolimus, and discuss the mechanism of drug action, the adverse effects and the challenges of treating a kidney ...
Kagiso G Motse, Mduduzi J Mashabane
openaire +4 more sources
Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial. [PDF]
PLoS ONE, 2012 Sirolimus has been approved for clinical use in non proliferative and proliferative disorders. It inhibits the mammalian target of rapamycin (mTOR) signaling pathway which is also known to regulate ovarian morphology and function.
Matthias Braun +14 more
doaj +1 more source
mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma
Molecular BiomedicineSirolimus is a regularly applied immunosuppressant for patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). Sirolimus not only significantly inhibits HCC recurrence but also protects renal function.
Lincheng Zhang +14 more
doaj +1 more source
In vitro pharmacokinetics of sirolimus-coated stent for tracheal stenosis [PDF]
, 2017 Purpose: To investigate the in vitro pharmacokinetics of sirolimus-coated stent for tracheal stenosisMethods: Naked nickel titanium alloy stent was placed in methylene chloride leaching solution with different ratios of sirolimus/poly(lactic-co-glycolic ...
Chen, Zhengxian +5 more
core +2 more sources
Engineering the Immune Response to Biomaterials
Advanced Science, EarlyView.This paper reviews immune responses to biomaterials, stages of evolution in relation to managing these responses ranging from preventing to modulating them. It also discusses state‐of‐the‐art strategies to modulate these responses and modes of their delivery.
Abolfazl Salehi Moghaddam +12 more
wiley +1 more source
Bioactive Materials, 2020 Pharmacokinetic analyses were performed using 20 pigs for 120-days implantation, while one sirolimus-eluting stent was implanted into one of their coronary artery.
Shanshan Chen +8 more
doaj
Development and Physicochemical Characterization of Sirolimus Solid Dispersions Prepared by Solvent Evaporation Method [PDF]
Advanced Pharmaceutical Bulletin, 2014 Purpose: The aim of the present investigation was preparation and characterization of sirolimus solid dispersions by solvent evaporation technique to improve its dissolution properties.
Shahram Emami +3 more
doaj +1 more source
Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and non-mTOR-mediated etiologies. [PDF]
, 2018 The present study was designed to examine the potential cellular antiseizure mechanisms of everolimus, a mechanistic target of rapamycin (mTOR) pathway blocker, in pediatric epilepsy cases. Cortical tissue samples obtained from pediatric patients (n
Barry, Joshua +8 more
core +2 more sources